MPG.eBooks - Search Results

1

Clinical and economic review report: Vedolizumab (ENTYVIO SC) Takeda Canada Inc. : indication: Crohn disease

Published 2021

Canadian Agency for Drugs and Technologies in Health

“...CADTH common drug review Clinical and economic review report for Vedolizumab (Entyvio SC)...”

Read Now

2

CADTH Canadian Drug Expert Committee recommendation: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza -- Janssen Inc.) : indication: treatment of HIV type 1 (HIV-1...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cobicistat / economics...”

Read Now

3

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Omalizumab / economics...”

Read Now

4

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Omalizumab / economics...”

Read Now

5

Pharmacoeconomic review report: Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Thiophenes / economics...”

Read Now

6

CADTH Canadian Drug Expert Committee recommendation: Tenofovir alafenamide (Vemlidy -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis B.

Published 2018

CADTH

Subjects: “...Antiviral Agents / economics...”

Read Now

7

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive mult...

Published 2018

CADTH

Subjects: “...Immunologic Factors / economics...”

Read Now

8

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Ivabradine / economics...”

Read Now

9

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Ivabradine / economics...”

Read Now

10

CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Pharmaceutical Services / economics...”

Read Now

11

CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Pharmaceutical Services / economics...”

Read Now

12

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Antibodies, Monoclonal, Humanized / economics...”

Read Now

13

Pharmacoeconomic review report: Tiotropium bromide monohydrate (Spiriva respimat) for inhalation

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Tiotropium Bromide / economics...”

Read Now

14

Pharmacoeconomic review report: Tiotropium bromide monohydrate (Spiriva respimat) for inhalation

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Tiotropium Bromide / economics...”

Read Now

15

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Antibodies, Monoclonal, Humanized / economics...”

Read Now

16

Robot-assisted surgery compared with open surgery and laparoscopic surgery : clinical effectiveness and economic analyses

by Ho, Chuong
Published 2011

Canadian Agency for Drugs and Technologies in Health

“... procedures and laparoscopic procedures, followed by a systematic review of economic evaluation studies. We...”

Read Now

17

CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Pharmaceutical Services / economics...”

Read Now

18

CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Insurance, Pharmaceutical Services / economics...”

Read Now

19

Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses : an economic analysis and budget impact analysis

by Membe, Stephen K.
Published 2011

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Plasma Substitutes / economics...”

Read Now

20

Pharmacoeconomic review report: Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and sym...

Published 2020

CADTH

Subjects: “...Drug Therapy, Combination / economics...”

Narrow Search